Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Bought by Boothbay Fund Management LLC

Boothbay Fund Management LLC boosted its holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 24.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 693,693 shares of the company's stock after acquiring an additional 136,264 shares during the period. Boothbay Fund Management LLC owned 1.55% of Y-mAbs Therapeutics worth $5,432,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in YMAB. Virtus ETF Advisers LLC increased its position in shares of Y-mAbs Therapeutics by 30.9% in the fourth quarter. Virtus ETF Advisers LLC now owns 35,789 shares of the company's stock worth $280,000 after purchasing an additional 8,457 shares during the period. Marshall Wace LLP increased its position in Y-mAbs Therapeutics by 217.4% in the 4th quarter. Marshall Wace LLP now owns 49,225 shares of the company's stock valued at $385,000 after acquiring an additional 33,716 shares during the period. Jump Financial LLC acquired a new stake in shares of Y-mAbs Therapeutics during the fourth quarter worth $261,000. XTX Topco Ltd increased its position in shares of Y-mAbs Therapeutics by 83.8% during the fourth quarter. XTX Topco Ltd now owns 20,768 shares of the company's stock worth $163,000 after buying an additional 9,468 shares during the period. Finally, Barclays PLC increased its position in shares of Y-mAbs Therapeutics by 9.6% during the fourth quarter. Barclays PLC now owns 75,862 shares of the company's stock worth $594,000 after buying an additional 6,640 shares during the period. Institutional investors own 70.85% of the company's stock.

Y-mAbs Therapeutics Trading Down 0.7 %

Shares of YMAB stock traded down $0.03 during midday trading on Tuesday, reaching $4.20. 152,403 shares of the stock were exchanged, compared to its average volume of 327,420. Y-mAbs Therapeutics, Inc. has a 1 year low of $3.84 and a 1 year high of $17.78. The firm has a market cap of $189.92 million, a PE ratio of -7.78 and a beta of 0.71. The company's 50 day moving average is $4.79 and its two-hundred day moving average is $8.01.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last issued its quarterly earnings results on Tuesday, March 4th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.02). The company had revenue of $26.50 million for the quarter, compared to the consensus estimate of $26.70 million. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. During the same quarter in the previous year, the business earned ($0.02) earnings per share. As a group, equities analysts expect that Y-mAbs Therapeutics, Inc. will post -0.65 EPS for the current fiscal year.

Insider Buying and Selling

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 10,810 shares of the business's stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $5.23, for a total transaction of $56,536.30. Following the sale, the insider now owns 202,721 shares of the company's stock, valued at approximately $1,060,230.83. The trade was a 5.06 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 22.50% of the stock is owned by corporate insiders.

Analyst Ratings Changes

YMAB has been the topic of a number of recent analyst reports. Wedbush reissued an "outperform" rating and set a $23.00 price target on shares of Y-mAbs Therapeutics in a research report on Monday, March 3rd. Bank of America lowered Y-mAbs Therapeutics from a "neutral" rating to an "underperform" rating and set a $3.00 price objective for the company. in a research note on Tuesday, April 22nd. Morgan Stanley dropped their price target on Y-mAbs Therapeutics from $11.00 to $7.00 and set an "underweight" rating for the company in a research note on Wednesday, March 5th. HC Wainwright dropped their price target on Y-mAbs Therapeutics from $22.00 to $12.00 and set a "buy" rating for the company in a research note on Friday, March 21st. Finally, Truist Financial lowered their target price on Y-mAbs Therapeutics from $21.00 to $18.00 and set a "buy" rating for the company in a research note on Wednesday, March 5th. Two investment analysts have rated the stock with a sell rating, seven have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $17.40.

Y-mAbs Therapeutics Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.